Latest Conference Articles

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.

As part of the 2020 ASCO Direct Highlights™ webcast, Brian Rini, MD, discusses key developments in genitourinary cancers that were presented during the 2020 ASCO Virtual Scientific Program.

A panel of experts in acute lymphoblastic leukemia broach the topic of innovative approaches incorporating novel agents in clinical practice.

A panel of experts in acute myeloid leukemia (AML) consider potential treatment options for patients with AML

A panel of experts in chronic myeloid leukemia share insight on how to optimally approach treatment based on patient characteristics.

Noopur Raje, MD, discusses the current challenges faced in the multiple myeloma treatment paradigm.

Lori Leslie, MD, discusses key questions to address with future research efforts in mantle cell lymphoma.

Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.

The treatment landscape of advanced hepatocellular carcinoma has been subject to rapid development in the last few years, says Amit G. Singal, MD, MS.

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.

Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.

EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.

Ghassan K. Abou-Alfa, MD, discusses the design and aim of the PROOF trial in advanced cholangiocarcinoma.

Ghassan K. Abou-Alfa, MD, discusses key eligibility criteria for the phase 3 PROOF trial in cholangiocarcinoma.

The safety and efficacy of maintenance olaparib in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial.

Yu Sunakawa, MD, PhD, further discusses the early real-world data from the DELIVER trial with nivolumab in patients with gastric/GEJ cancer and provided insight into what future analyses will examine.

Manish R. Patel, DO, further discusses next steps for entrectinib, as well as the need for genetic testing to identify uncommon gene rearrangements in GI malignancies.

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from a study of combination durvalumab and tremelimumab, as well as the clinical need for alternative combination regimens in advanced hepatcellular carcinoma.

The regimen of liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.

Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from the long-term analysis of the CheckMate-459 trial in advanced hepatocellular carcinoma.